Ekso Bionics Holdings, INC.: management transactions · United States · SEC (Form 4)

About Ekso Bionics Holdings, INC.

Ekso Bionics Holdings, Inc. is a U.S.-based robotics and medical technology company listed on the Nasdaq Capital Market in the United States under the ticker EKSO. The company was founded in 2005 and is headquartered in the San Francisco Bay Area, with operating roots in San Rafael, California. Its core business is the design, development, and commercialization of exoskeletons and complementary products intended to augment human strength, endurance, and mobility. For investors, Ekso Bionics sits at the intersection of medtech, robotics, and assistive technology. The company’s commercial model is centered on two end markets: Enterprise Health and Personal Health. In Enterprise Health, Ekso’s flagship product is EksoNR, a wearable robotic exoskeleton used in clinical rehabilitation settings for patients recovering from spinal cord injury, stroke, traumatic brain injury, and multiple sclerosis. The company also offers Ekso Indego Therapy, a lightweight, modular, lower-limb powered exoskeleton used in rehabilitation and wellness applications. In Personal Health, Ekso Indego Personal is designed to help individuals with mobility impairments—particularly people with spinal cord injuries—achieve overground walking in home and community settings. Ekso also has an industrial exposure through Ekso EVO, an upper-body wearable exoskeleton aimed at reducing worker fatigue and injury risk in repetitive overhead tasks. The company targets industries such as aerospace, automotive, general manufacturing, and selected construction trades. Beyond hardware sales, Ekso provides support and service offerings through EksoCare, including extended warranty, loaner devices, clinical support, and training. This service layer can help increase customer stickiness and support recurring revenue characteristics over time. From a competitive standpoint, Ekso operates in an emerging market where adoption depends on clinical evidence, reimbursement coverage, regulatory approvals, and customer education. Its positioning is supported by FDA clearances, a long operating history since 2005, and a focused product portfolio. A notable recent development was Medicare reimbursement approval for Ekso Indego Personal in 2024, which may expand access in the U.S. patient population. In 2025, the company announced new distribution for Indego Personal, joined the NVIDIA Connect program to develop AI capabilities related to human motion, and advanced its European footprint through CE/MDR certification. However, the company remains a small-cap, high-risk name with ongoing cash burn and reliance on external financing or strategic partnerships to fund growth and product development.